All results
1 results
-
Tazemetostat in patients with recurrent/refractory and/or metastatic MPNST
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant…
- Ages
- 12 Years - 99 Years
- Sexes
- All